Is CINQAIR Right for Your Patient?

CINQAIR offers weight-based dosing for adult patients with
severe asthma and an eosinophilic phenotype1

Administered by an HCP

CINQAIR is for IV infusion only. Do not administer as IV push or bolus.1

  • HCP administration in each infusion setting helps ensure consistent dosing and administration
  • Dosing schedule and IV administration enable severe asthmatic patients to have monthly contact with an HCP
    • IV doses of 3 mg/kg once every 4 weeks
  • Administered by an HCP in as little as 20-50 minutes*
  • An option for patients who cannot or do not want to self-inject
  • Provides visibility to delayed or missed doses
  • 100% bioavailability1,2

HCP=healthcare professional; IV=intravenous.

*Monitor patients during the infusion and for an appropriate time afterward.1

Test your patients’ blood eosinophil levels

Consider ordering a complete blood count with differential diagnosis
for your patients with severe asthma.3

Access a calculator to convert the percentage of eosinophils to an absolute eosinophil count (cells/mcL).

REFERENCES: 1. CINQAIR Prescribing Information. West Chester, PA. Teva Respiratory, LLC. 2. Cyriac JM, James E. Switch over from intravenous to oral therapy: a concise overview. J Pharmacol Pharmacother. 2014;5(2):83-87. 3. Data on file (clinical study report: a 12-month, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of reslizumab [3.0 mg/kg] in the reduction of clinical asthma exacerbations in patients [12-75 years of age] with eosinophilic asthma. Study C38072/3083). Parsippany, NJ. Teva Respiratory, LLC. February 2015.